PUBLISHER: Meticulous Research | PRODUCT CODE: 2138405
PUBLISHER: Meticulous Research | PRODUCT CODE: 2138405
NGS Services Market Size, Share, and Industry Analysis by Type, Technology, Application, End User, and Geography - Global Forecast to 2036
The global Next Generation Sequencing Services Market was valued at USD 7,291.0 million in 2025. It is estimated to reach USD 8,473.5 million in 2026 and is projected to grow to USD 33,728.0 million by 2036, at a CAGR of 14.8% during the forecast period. This report offers a detailed look at the market, covering sequencing costs, clinical and research demand, sequencing technologies, service providers, regulatory and reimbursement developments, data analysis, national genome programs, and future growth opportunities.
Next generation sequencing services are outsourced sequencing activities provided to pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, academic institutes, research centers, and other users that do not operate their own sequencing platforms or require specialized sequencing capacity. These services include targeted sequencing, RNA sequencing, whole genome sequencing, exome sequencing, de novo sequencing, methyl sequencing, ChIP sequencing, and other NGS services delivered using sequencing by synthesis, ion semiconductor, single molecule real time, nanopore, and DNA nanoball technologies.
The economics of sequencing continue to support service providers. The cost of sequencing a human genome has fallen from about USD 29,092 in 2010 to USD 562 in 2021, while high throughput platforms can now deliver a genome at approximately USD 200. However, production sequencing systems can cost around USD 1 million, with additional investments required for library preparation, data storage, computing, and bioinformatics. This creates an economic advantage for centralized service providers that operate sequencing systems at high utilization rates.
Clinical demand is becoming an increasingly important source of market growth. Rising cancer incidence, growing use of genomic profiling in treatment selection, liquid biopsy and minimal residual disease testing, rare disease diagnosis, reproductive health testing, and infectious disease surveillance are expanding the use of sequencing services. At the same time, national genome programs and increasing outsourcing of sequencing in pharmaceutical research and drug development are supporting demand from research applications.
The report examines market drivers and restraints, sequencing costs and economics, clinical and research applications, technology developments, the market ecosystem and value chain, regulatory and reimbursement developments, data privacy requirements, national genome programs, and investment trends. It explains why targeted sequencing services and sequencing by synthesis account for the largest shares of the market, why clinical applications are growing faster than research applications, and how long read sequencing, methylation sequencing, single cell sequencing, and multiomics services are creating new opportunities. It also provides market forecasts, segment level insights, and regional analysis across 5 regions and 20+ countries and subregions to support business, investment, capacity planning, and market entry decisions.
Market Dynamics
The declining cost of sequencing is one of the main forces behind market growth. Lower sequencing costs have made whole genome, exome, targeted, and RNA sequencing more accessible for clinical testing, large research studies, population genomics programs, and drug development. Centralized service providers can further reduce the cost per sample by operating high throughput sequencing systems at high utilization rates.
Rising cancer incidence is adding significant demand for NGS services, particularly for genomic profiling, targeted therapy selection, liquid biopsy, and minimal residual disease testing. According to the International Agency for Research on Cancer, around 20 million new cancer cases were reported globally in 2022, and the number is projected to exceed 35 million by 2050. Sequencing based tests are increasingly being incorporated into cancer care and clinical decision making.
The high cost of establishing and operating in house sequencing capacity continues to support outsourcing. Sequencing laboratories require expensive instruments, library preparation systems, data storage, computing infrastructure, bioinformatics capabilities, and trained personnel. In addition, specialized applications such as long read, single cell, spatial, and multiomic sequencing require dedicated technologies and expertise, encouraging hospitals, pharmaceutical companies, and research organizations to purchase these services rather than build the capabilities internally.
Clinical sequencing is also expanding beyond oncology. Non invasive prenatal testing, carrier screening, rare disease diagnosis, infectious disease surveillance, and other applications are increasing the use of NGS services. Regulatory approvals, clinical guideline inclusion, and payer coverage are further supporting the transition of sequencing based tests into routine clinical pathways.
However, large hospitals, academic medical centers, and research institutes are increasingly installing their own sequencing systems to reduce turnaround times, retain samples and genomic data internally, and capture testing revenue. In addition, PCR, Sanger sequencing, microarrays, fluorescence in situ hybridization, and immunohistochemistry continue to compete with NGS for specific applications. Data privacy requirements, regulatory differences between countries, the shortage of skilled bioinformatics and clinical interpretation professionals, and the complexity of interpreting genomic variants also create challenges for service providers.
Long read sequencing, methylation based testing, single cell sequencing, and multiomics represent important opportunities for service providers. These technologies can address applications that are difficult to resolve using conventional short read sequencing, including structural variants, repeat expansions, phasing, methylation, and cell specific gene expression. National genome programs in countries across Asia Pacific and the Middle East are also creating large scale sequencing requirements that can be served by specialized providers.
Segment Analysis
The report analyzes the market by type, technology, application, end user, and geography, helping stakeholders identify the major growth opportunities across the NGS services ecosystem.
Based on type, the market is segmented into targeted sequencing services, RNA sequencing services, whole genome sequencing services, exome sequencing services, de novo sequencing services, methyl sequencing services, ChIP sequencing services, and other NGS services. In 2026, targeted sequencing services are expected to account for the largest share of 27.2% of the market, supported by their lower cost, higher sequencing depth, and routine use in cancer genomic profiling and liquid biopsy. However, methyl sequencing services are projected to grow the fastest, with a CAGR of 15.6% during the forecast period, followed by whole genome sequencing services at 15.4%.
Based on technology, the market is segmented into sequencing by synthesis, ion semiconductor sequencing, single molecule real time sequencing, nanopore sequencing, and DNA nanoball sequencing. In 2026, sequencing by synthesis is expected to account for the largest share of 63.5%, supported by the large installed base of Illumina platforms among service providers and its relatively low cost per base. However, nanopore sequencing is projected to register the highest CAGR of 15.6% during the forecast period, supported by growing demand for long read sequencing and applications requiring structural variant and methylation analysis.
Based on application, the market is segmented into research applications, including drug discovery, agriculture and animal research, and other research applications, and clinical applications, including oncology, reproductive health, infectious diseases, and other clinical applications. In 2026, research applications are expected to account for the larger share of 55.5%, primarily due to the extensive use of outsourced sequencing in drug discovery and development. However, clinical applications are projected to register the higher CAGR of 15.9%, with oncology expected to grow at the highest CAGR of 16.8% within clinical applications.
Based on end user, the market is segmented into hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies, academic institutes and research centers, and other end users. In 2026, hospitals and diagnostic laboratories are expected to account for the largest share of 44.9% of the NGS services market. The large share of this segment is attributed to the concentration of complex clinical sequencing in specialized reference laboratories. This segment is also projected to register the highest CAGR of 15.7% during the forecast period.
Regional Analysis
The report covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, spanning major countries and subregions. The regional analysis considers sequencing infrastructure, clinical genomics adoption, pharmaceutical and biotechnology research, national genome programs, reimbursement, regulatory developments, sequencing providers, and investments in genomic medicine.
In 2026, North America is expected to account for the largest share of 44.0% of the global NGS Services Market, with the U.S. accounting for the largest share of the regional market. The region's large share is supported by the concentration of clinical sequencing laboratories and commercial genomics providers, Medicare coverage for NGS based cancer testing, high pharmaceutical R&D spending, and large genomic research programs such as the All of Us Research Program.
Europe is expected to account for the second largest share of 27.8% of the NGS services market in 2026. The region benefits from national genomic medicine programs in the U.K., Germany, and France, a large pharmaceutical and research base, and the presence of major sequencing service providers. Germany is expected to account for the largest share of the European market.
Asia Pacific is projected to grow the fastest, registering a CAGR of 17.5% during the forecast period. The growth of the region is supported by the scale of sequencing providers in China, national genome programs in India, South Korea, Singapore, and Japan, increasing pharmaceutical R&D spending and outsourcing, and lower sequencing prices offered by domestic platforms. China is expected to account for the largest share of the regional market in 2026, while India is projected to register the highest country level CAGR of 19.7%.
In Latin America, Brazil is expected to account for the largest share of the regional market in 2026, supported by increasing use of sequencing in oncology and prenatal screening, pharmaceutical clinical trial activity, and national genomics initiatives such as the Genomas Brasil program. In the Middle East & Africa, the market is supported by national genome programs, investments in genomic medicine infrastructure, and the growing use of sequencing for genetic disease screening.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive assessment, market and geographic coverage, service capabilities, regulatory developments, and profiles of leading companies, including their financial performance, service portfolios, strategic developments, and competitive positioning.
The NGS services market combines clinical sequencing laboratories, commercial genomics providers, contract research organizations, and platform companies offering sequencing services. Companies compete on service breadth, turnaround time, data quality, regulatory approvals, payer coverage, price per sample, bioinformatics and interpretation capabilities, and geographic reach. Regulatory approvals and reimbursement developments have become important competitive factors as sequencing moves into routine clinical pathways.
Based on the 2025 market ranking presented in the report, Natera, Guardant Health, and Roche through Foundation Medicine are among the leading participants, followed by BGI Genomics and Labcorp. Key companies profiled in the report include Illumina, Inc., Eurofins Scientific SE, Labcorp Holdings Inc., F. Hoffmann-La Roche Ltd, BGI Genomics Co., Ltd., Novogene Co., Ltd., Revvity, Inc., Macrogen, Inc., QIAGEN N.V., Azenta, Inc., GeneDx Holdings Corp., Natera, Inc., Guardant Health, Inc., and Quest Diagnostics Incorporated.
The competitive landscape is also being shaped by new sequencing platforms and specialized service categories. The entry of platforms from Roche, Element Biosciences, and Ultima Genomics is increasing competition in sequencing costs, while growing demand for methylation, long read, single cell, spatial, and multiomic sequencing is creating opportunities for providers with specialized capabilities.
How This Report Helps
- Provides reliable market size estimates and long term forecasts for the global next generation sequencing services market.
- Explains how declining sequencing costs, cancer prevalence, clinical genomic testing, pharmaceutical research, national genome programs, and outsourcing affect market growth.
- Identifies high growth opportunities across type, technology, application, end user, and region.
- Analyzes sequencing technologies, service economics, regulatory developments, reimbursement trends, data requirements, and emerging applications shaping the market.
- Assesses the shift from research sequencing toward clinical applications, including oncology, reproductive health, rare diseases, and infectious disease testing.
- Benchmarks leading companies based on their service capabilities, technology coverage, geographic presence, strategic developments, and competitive positioning.
- Supports capacity planning, service portfolio development, partnership and acquisition evaluation, investment planning, and market entry decisions.
- Delivers practical market insights for sequencing service providers, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, academic and research institutions, technology providers, and investors.
Key Questions Answered
- How big is the global next generation sequencing services market today, and how will it grow through 2036?
- How are declining sequencing costs, cancer incidence, genomic profiling, pharmaceutical research, and national genome programs driving demand?
- What are the main drivers, restraints, opportunities, and challenges shaping the NGS services industry?
- Which type, technology, application, end user, and regional segments will grow the fastest?
- Why are pharmaceutical companies, hospitals, and research organizations outsourcing sequencing services?
- How are clinical applications changing the demand for NGS services?
- How are regulatory, reimbursement, data privacy, and laboratory requirements affecting the market?
- How are long read sequencing, methylation sequencing, single cell sequencing, and multiomic services creating new opportunities?
- How is the installation of in house sequencing capacity affecting NGS service providers?
- Which regions and countries offer significant growth opportunities for NGS service providers?
- Who are the leading companies operating in the NGS services market, and what strategies are they adopting?
- What recent technology launches, regulatory approvals, reimbursement developments, and strategic initiatives are shaping the competitive landscape?
TABLE OF CONTENTS
1. Introduction
- 1.1. Market Definition & Scope
- 1.2. Market Ecosystem
- 1.3. Currency & Limitations
- 1.4. Key Stakeholders
2. Research Methodology
- 2.1. Research Approach
- 2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
- 2.3. Market Assessment
- 2.3.1. Market Size Estimation
- 2.3.2. Bottom-Up Approach
- 2.3.3. Top-Down Approach
- 2.3.4. Growth Forecast
- 2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
- 4.1. Overview
- 4.2. Factors Affecting Market Growth
- 4.2.1. Drivers
- 4.2.1.1. Declining Costs of Sequencing Driving Demand for NGS Services
- 4.2.1.2. Rising Prevalence of Cancer and Growing Use of Genomic Profiling Driving Clinical Sequencing Services
- 4.2.1.3. High Cost of Building In-House Sequencing Capacity Favoring Outsourcing
- 4.2.1.4. Surge in National Genome Sequencing Programs Driving Demand for Large-Scale Services
- 4.2.1.5. Increasing Use of Sequencing in Drug Development Driving Outsourced Sequencing
- 4.2.2. Restraints
- 4.2.2.1. Availability of Alternative Technologies Restraining Market Growth
- 4.2.2.2. Lack of Skilled Professionals for Sample Preparation and Interpretation Restraining Market Growth
- 4.2.3. Opportunities
- 4.2.3.1. Expanding Clinical Sequencing in Reproductive Health, Rare Diseases and Infectious Diseases Generating Opportunities
- 4.2.3.2. Growth of Long-Read, Single-Cell and Multiomic Services Generating Opportunities
- 4.2.3.3. Return of Laboratory Developed Tests to CLIA Oversight Generating Opportunities for Clinical Service Laboratories
- 4.2.4. Challenges
- 4.2.4.1. Installation of In-House NGS Systems by Large Hospitals and Research Institutes
- 4.2.4.2. Data Security, Privacy and Cross-Border Data Transfer Restrictions
- 4.2.4.3. U.S. Restrictions on Biotechnology Companies of Concern
- 4.2.1. Drivers
- 4.3. Key Trends
- 4.3.1. Shift of Sequencing Demand from Research to Clinical Applications
- 4.3.2. Consolidation and Restructuring Among Service Providers
- 4.3.3. Entry of New Sequencing Platforms
- 4.3.4. Clinical Sequencing Tests Entering Guidelines and Coverage
- 4.3.5. Integration of Bioinformatics and Artificial Intelligence into Services
- 4.4. Regulatory Analysis
- 4.4.1. North America
- 4.4.2. Europe
- 4.4.3. Asia-Pacific
- 4.4.4. Latin America
- 4.4.5. Middle East & Africa
- 4.5. Pricing Analysis
- 4.6. Porter's Five Forces Analysis
- 4.6.1. Bargaining Power of Buyers
- 4.6.2. Bargaining Power of Suppliers
- 4.6.3. Threat of Substitutes
- 4.6.4. Threat of New Entrants
- 4.6.5. Degree of Competition
- 4.7. Value Chain Analysis
- 4.7.1. Platform and Reagent Supply
- 4.7.2. Sample Collection and Logistics
- 4.7.3. Library Preparation and Sequencing
- 4.7.4. Data Analysis and Interpretation
- 4.7.5. End Use
5. NGS Services Market Assessment, by Type
- 5.1. Overview
- 5.2. Targeted Sequencing Services
- 5.3. RNA Sequencing Services
- 5.4. Whole Genome Sequencing Services
- 5.5. Exome Sequencing Services
- 5.6. De Novo Sequencing Services
- 5.7. Methyl Sequencing Services
- 5.8. ChIP Sequencing Services
- 5.9. Other NGS Services
6. NGS Services Market Assessment, by Technology
- 6.1. Overview
- 6.2. Sequencing by Synthesis
- 6.3. Ion Semiconductor Sequencing
- 6.4. Single-Molecule Real-Time Sequencing
- 6.5. Nanopore Sequencing
- 6.6. DNA Nanoball Sequencing
7. NGS Services Market Assessment, by Application
- 7.1. Overview
- 7.2. Research Applications
- 7.2.1. Drug Discovery
- 7.2.2. Agriculture & Animal Research
- 7.2.3. Other Research Applications
- 7.3. Clinical Applications
- 7.3.1. Oncology
- 7.3.2. Reproductive Health
- 7.3.3. Infectious Diseases
- 7.3.4. Other Clinical Applications
8. NGS Services Market Assessment, by End User
- 8.1. Overview
- 8.2. Hospitals & Diagnostic Laboratories
- 8.3. Pharmaceutical & Biotechnology Companies
- 8.4. Academic Institutes & Research Centers
- 8.5. Other End Users
9. NGS Services Market Assessment, by Geography
- 9.1. Overview
- 9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
- 9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Rest of Europe
- 9.4. Asia-Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. India
- 9.4.4. Rest of Asia-Pacific
- 9.5. Latin America
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 9.6. Middle East & Africa
10. Competitive Landscape
- 10.1. Overview
- 10.2. Key Growth Strategies
- 10.3. Competitive Benchmarking
- 10.4. Competitive Dashboard
- 10.4.1. Industry Leaders
- 10.4.2. Market Differentiators
- 10.4.3. Vanguards
- 10.5. Market Ranking, 2025
11. Company Profiles
- 11.1. Illumina, Inc. (U.S.)
- 11.1.1. Company Overview
- 11.1.2. Financial Overview
- 11.1.3. Product and Service Portfolio
- 11.1.4. Strategic Developments
- 11.1.5. SWOT Analysis
- 11.2. Eurofins Scientific SE (Luxembourg)
- 11.2.1. Company Overview
- 11.2.2. Financial Overview
- 11.2.3. Product and Service Portfolio
- 11.2.4. Strategic Developments
- 11.2.5. SWOT Analysis
- 11.3. Labcorp Holdings Inc. (U.S.)
- 11.3.1. Company Overview
- 11.3.2. Financial Overview
- 11.3.3. Product and Service Portfolio
- 11.3.4. Strategic Developments
- 11.3.5. SWOT Analysis
- 11.4. F. Hoffmann-La Roche Ltd (Switzerland)
- 11.4.1. Company Overview
- 11.4.2. Financial Overview
- 11.4.3. Product and Service Portfolio
- 11.4.4. Strategic Developments
- 11.4.5. SWOT Analysis
- 11.5. BGI Genomics Co., Ltd. (China)
- 11.5.1. Company Overview
- 11.5.2. Financial Overview
- 11.5.3. Product and Service Portfolio
- 11.5.4. Strategic Developments
- 11.5.5. SWOT Analysis
- 11.6. Novogene Co., Ltd. (China)
- 11.6.1. Company Overview
- 11.6.2. Financial Overview
- 11.6.3. Product and Service Portfolio
- 11.6.4. Strategic Developments
- 11.6.5. SWOT Analysis
- 11.7. Revvity, Inc. (U.S.)
- 11.7.1. Company Overview
- 11.7.2. Financial Overview
- 11.7.3. Product and Service Portfolio
- 11.7.4. Strategic Developments
- 11.7.5. SWOT Analysis
- 11.8. Macrogen, Inc. (South Korea)
- 11.8.1. Company Overview
- 11.8.2. Financial Overview
- 11.8.3. Product and Service Portfolio
- 11.8.4. Strategic Developments
- 11.8.5. SWOT Analysis
- 11.9. QIAGEN N.V. (Netherlands)
- 11.9.1. Company Overview
- 11.9.2. Financial Overview
- 11.9.3. Product and Service Portfolio
- 11.9.4. Strategic Developments
- 11.9.5. SWOT Analysis
- 11.10. Azenta, Inc. (U.S.)
- 11.10.1. Company Overview
- 11.10.2. Financial Overview
- 11.10.3. Product and Service Portfolio
- 11.10.4. Strategic Developments
- 11.10.5. SWOT Analysis
- 11.11. GeneDx Holdings Corp. (U.S.)
- 11.11.1. Company Overview
- 11.11.2. Financial Overview
- 11.11.3. Product and Service Portfolio
- 11.11.4. Strategic Developments
- 11.11.5. SWOT Analysis
- 11.12. Natera, Inc. (U.S.)
- 11.12.1. Company Overview
- 11.12.2. Financial Overview
- 11.12.3. Product and Service Portfolio
- 11.12.4. Strategic Developments
- 11.12.5. SWOT Analysis
- 11.13. Guardant Health, Inc. (U.S.)
- 11.13.1. Company Overview
- 11.13.2. Financial Overview
- 11.13.3. Product and Service Portfolio
- 11.13.4. Strategic Developments
- 11.13.5. SWOT Analysis
- 11.14. Quest Diagnostics Incorporated (U.S.)
- 11.14.1. Company Overview
- 11.14.2. Financial Overview
- 11.14.3. Product and Service Portfolio
- 11.14.4. Strategic Developments
- 11.14.5. SWOT Analysis
12. Appendix
- 12.1. Available Customization
- 12.2. Related Reports
LIST OF TABLES
List of Tables
- Table 1 Key Secondary Sources
- Table 2 Major National Genome Sequencing Programs
- Table 3 NGS Services: Standards and Compliance Guidelines for Laboratories
- Table 4 Indicative Pricing of NGS Services, 2025-2026
- Table 5 Global NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 6 Global Targeted Sequencing Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 7 Global RNA Sequencing Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 8 Global Whole Genome Sequencing Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 9 Global Exome Sequencing Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 10 Global De Novo Sequencing Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 11 Global Methyl Sequencing Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 12 Global ChIP Sequencing Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 13 Global Other NGS Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 14 Global NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 15 Global NGS Services Market for Sequencing by Synthesis, by Country/Region, 2024-2036 (USD Million)
- Table 16 Global NGS Services Market for Ion Semiconductor Sequencing, by Country/Region, 2024-2036 (USD Million)
- Table 17 Global NGS Services Market for Single-Molecule Real-Time Sequencing, by Country/Region, 2024-2036 (USD Million)
- Table 18 Global NGS Services Market for Nanopore Sequencing, by Country/Region, 2024-2036 (USD Million)
- Table 19 Global NGS Services Market for DNA Nanoball Sequencing, by Country/Region, 2024-2036 (USD Million)
- Table 20 Global NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 21 Global NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 22 Global NGS Services Market for Research Applications, by Country/Region, 2024-2036 (USD Million)
- Table 23 Global NGS Services Market for Drug Discovery, by Country/Region, 2024-2036 (USD Million)
- Table 24 Global NGS Services Market for Agriculture & Animal Research, by Country/Region, 2024-2036 (USD Million)
- Table 25 Global NGS Services Market for Other Research Applications, by Country/Region, 2024-2036 (USD Million)
- Table 26 Global NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 27 Global NGS Services Market for Clinical Applications, by Country/Region, 2024-2036 (USD Million)
- Table 28 Global NGS Services Market for Oncology, by Country/Region, 2024-2036 (USD Million)
- Table 29 Global NGS Services Market for Reproductive Health, by Country/Region, 2024-2036 (USD Million)
- Table 30 Global NGS Services Market for Infectious Diseases, by Country/Region, 2024-2036 (USD Million)
- Table 31 Global NGS Services Market for Other Clinical Applications, by Country/Region, 2024-2036 (USD Million)
- Table 32 Global NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 33 Global NGS Services Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2024-2036 (USD Million)
- Table 34 Global NGS Services Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2024-2036 (USD Million)
- Table 35 Global NGS Services Market for Academic Institutes & Research Centers, by Country/Region, 2024-2036 (USD Million)
- Table 36 Global NGS Services Market for Other End Users, by Country/Region, 2024-2036 (USD Million)
- Table 37 Global NGS Services Market, by Region, 2024-2036 (USD Million)
- Table 38 North America: NGS Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 39 North America: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 40 North America: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 41 North America: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 42 North America: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 43 North America: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 44 North America: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 45 U.S.: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 46 U.S.: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 47 U.S.: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 48 U.S.: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 49 U.S.: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 50 U.S.: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 51 Canada: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 52 Canada: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 53 Canada: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 54 Canada: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 55 Canada: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 56 Canada: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 57 Europe: NGS Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 58 Europe: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 59 Europe: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 60 Europe: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 61 Europe: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 62 Europe: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 63 Europe: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 64 Germany: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 65 Germany: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 66 Germany: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 67 Germany: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 68 Germany: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 69 Germany: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 70 France: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 71 France: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 72 France: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 73 France: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 74 France: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 75 France: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 76 U.K.: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 77 U.K.: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 78 U.K.: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 79 U.K.: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 80 U.K.: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 81 U.K.: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 82 Italy: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 83 Italy: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 84 Italy: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 85 Italy: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 86 Italy: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 87 Italy: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 88 Spain: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 89 Spain: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 90 Spain: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 91 Spain: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 92 Spain: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 93 Spain: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 94 Rest of Europe: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 95 Rest of Europe: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 96 Rest of Europe: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 97 Rest of Europe: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 98 Rest of Europe: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 99 Rest of Europe: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 100 Asia-Pacific: NGS Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 101 Asia-Pacific: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 102 Asia-Pacific: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 103 Asia-Pacific: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 104 Asia-Pacific: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 105 Asia-Pacific: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 106 Asia-Pacific: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 107 China: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 108 China: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 109 China: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 110 China: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 111 China: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 112 China: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 113 Japan: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 114 Japan: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 115 Japan: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 116 Japan: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 117 Japan: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 118 Japan: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 119 India: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 120 India: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 121 India: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 122 India: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 123 India: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 124 India: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 125 Rest of Asia-Pacific: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 126 Rest of Asia-Pacific: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 127 Rest of Asia-Pacific: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 128 Rest of Asia-Pacific: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 129 Rest of Asia-Pacific: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 130 Rest of Asia-Pacific: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 131 Latin America: NGS Services Market, by Country/Region, 2024-2036 (USD Million)
- Table 132 Latin America: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 133 Latin America: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 134 Latin America: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 135 Latin America: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 136 Latin America: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 137 Latin America: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 138 Brazil: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 139 Brazil: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 140 Brazil: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 141 Brazil: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 142 Brazil: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 143 Brazil: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 144 Mexico: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 145 Mexico: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 146 Mexico: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 147 Mexico: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 148 Mexico: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 149 Mexico: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 150 Rest of Latin America: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 151 Rest of Latin America: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 152 Rest of Latin America: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 153 Rest of Latin America: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 154 Rest of Latin America: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 155 Rest of Latin America: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 156 Middle East & Africa: NGS Services Market, by Type, 2024-2036 (USD Million)
- Table 157 Middle East & Africa: NGS Services Market, by Technology, 2024-2036 (USD Million)
- Table 158 Middle East & Africa: NGS Services Market, by Application, 2024-2036 (USD Million)
- Table 159 Middle East & Africa: NGS Services Market for Research Applications, by Type, 2024-2036 (USD Million)
- Table 160 Middle East & Africa: NGS Services Market for Clinical Applications, by Type, 2024-2036 (USD Million)
- Table 161 Middle East & Africa: NGS Services Market, by End User, 2024-2036 (USD Million)
- Table 162 NGS Services Market: Competitive Benchmarking, by Service Area
- Table 163 NGS Services Market: Market Ranking, 2025
- Table 164 Illumina, Inc.: Product and Service Portfolio
- Table 165 Illumina, Inc.: Strategic Developments, 2024-2026
- Table 166 Eurofins Scientific SE: Product and Service Portfolio
- Table 167 Eurofins Scientific SE: Strategic Developments, 2024-2026
- Table 168 Labcorp Holdings Inc.: Product and Service Portfolio
- Table 169 Labcorp Holdings Inc.: Strategic Developments, 2024-2026
- Table 170 F. Hoffmann-La Roche Ltd: Product and Service Portfolio
- Table 171 F. Hoffmann-La Roche Ltd: Strategic Developments, 2024-2026
- Table 172 BGI Genomics Co., Ltd.: Product and Service Portfolio
- Table 173 BGI Genomics Co., Ltd.: Strategic Developments, 2024-2026
- Table 174 Novogene Co., Ltd.: Product and Service Portfolio
- Table 175 Novogene Co., Ltd.: Strategic Developments, 2024-2026
- Table 176 Revvity, Inc.: Product and Service Portfolio
- Table 177 Revvity, Inc.: Strategic Developments, 2024-2026
- Table 178 Macrogen, Inc.: Product and Service Portfolio
- Table 179 Macrogen, Inc.: Strategic Developments, 2024-2026
- Table 180 QIAGEN N.V.: Product and Service Portfolio
- Table 181 QIAGEN N.V.: Strategic Developments, 2024-2026
- Table 182 Azenta, Inc.: Product and Service Portfolio
- Table 183 Azenta, Inc.: Strategic Developments, 2024-2026
- Table 184 GeneDx Holdings Corp.: Product and Service Portfolio
- Table 185 GeneDx Holdings Corp.: Strategic Developments, 2024-2026
- Table 186 Natera, Inc.: Product and Service Portfolio
- Table 187 Natera, Inc.: Strategic Developments, 2024-2026
- Table 188 Guardant Health, Inc.: Product and Service Portfolio
- Table 189 Guardant Health, Inc.: Strategic Developments, 2024-2026
- Table 190 Quest Diagnostics Incorporated: Product and Service Portfolio
- Table 191 Quest Diagnostics Incorporated: Strategic Developments, 2024-2026
LIST OF FIGURES
List of Figures
- Figure 1 NGS Services Market Ecosystem
- Figure 2 Research Process
- Figure 3 Primary Research Techniques
- Figure 4 Key Executives Interviewed
- Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
- Figure 6 Market Sizing and Growth Forecast Approach
- Figure 7 Global NGS Services Market, by Type, 2026 vs. 2036 (USD Million)
- Figure 8 Global NGS Services Market, by Technology, 2026 vs. 2036 (USD Million)
- Figure 9 Global NGS Services Market, by Application, 2026 vs. 2036 (USD Million)
- Figure 10 Global NGS Services Market, by End User, 2026 vs. 2036 (USD Million)
- Figure 11 NGS Services Market, by Geography
- Figure 12 Factors Affecting Market Growth
- Figure 13 Cost per Human Genome, 2010-2026 (USD)
- Figure 14 Porter's Five Forces Analysis
- Figure 15 Value Chain Analysis
- Figure 16 Global NGS Services Market, by Type, 2026 vs. 2036 (USD Million)
- Figure 17 Oncology Test Volumes at Leading Targeted Sequencing Service Providers, 2024 vs. 2025
- Figure 18 Sequencing Cost per Sample Before and After the Move to Novaseq X Plus at an Academic Core Facility (USD)
- Figure 19 Cost per Human Genome, 2010-2026 (USD)
- Figure 20 Genedx Exome and Genome Test Result Volume, 2022-2025
- Figure 21 Shield Blood-Based Colorectal Cancer Screening Test Volume, 2025 vs. 2026
- Figure 22 Global NGS Services Market, by Technology, 2026 vs. 2036 (USD Million)
- Figure 23 Pacific Biosciences Revenue, by Category, 2024 vs. 2025 (USD Million)
- Figure 24 Global NGS Services Market, by Application, 2026 vs. 2036 (USD Million)
- Figure 25 Global NGS Services Market for Research Applications, by Type, 2026 vs. 2036 (USD Million)
- Figure 26 Global NGS Services Market for Clinical Applications, by Type, 2026 vs. 2036 (USD Million)
- Figure 27 Oncology Test Volumes at Leading Targeted Sequencing Service Providers, 2024 vs. 2025
- Figure 28 Genedx Exome and Genome Test Result Volume, 2022-2025
- Figure 29 Global NGS Services Market, by End User, 2026 vs. 2036 (USD Million)
- Figure 30 Revenue of Leading Clinical Sequencing Laboratories, 2024 vs. 2025 (USD Million)
- Figure 31 NGS Services Market, by Geography
- Figure 32 Global NGS Services Market, by Region, 2026 vs. 2036 (USD Million)
- Figure 33 North America: NGS Services Market, by Country/Region, 2026 vs. 2036 (USD Million)
- Figure 34 U.S.: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 35 Canada: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 36 Europe: NGS Services Market, by Country/Region, 2026 vs. 2036 (USD Million)
- Figure 37 Germany: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 38 France: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 39 U.K.: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 40 Italy: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 41 Spain: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 42 Rest of Europe: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 43 Asia-Pacific: NGS Services Market, by Country/Region, 2026 vs. 2036 (USD Million)
- Figure 44 China: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 45 Japan: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 46 India: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 47 Rest of Asia-Pacific: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 48 Latin America: NGS Services Market, by Country/Region, 2026 vs. 2036 (USD Million)
- Figure 49 Brazil: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 50 Mexico: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 51 Rest of Latin America: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 52 Middle East & Africa: NGS Services Market Size, 2024-2036 (USD Million)
- Figure 53 NGS Services Market: Number of Strategic Developments, by Approach, January 2025-SEPTEMBER 2026
- Figure 54 NGS Services Market: Competitive Dashboard
- Figure 55 Illumina, Inc.: Financial Snapshot (2025)
- Figure 56 Illumina, Inc.: SWOT Analysis
- Figure 57 Eurofins Scientific SE: Financial Snapshot (2025)
- Figure 58 Eurofins Scientific SE: SWOT Analysis
- Figure 59 Labcorp Holdings Inc.: Financial Snapshot (2025)
- Figure 60 Labcorp Holdings Inc.: SWOT Analysis
- Figure 61 F. Hoffmann-La Roche Ltd: Financial Snapshot (2025)
- Figure 62 F. Hoffmann-La Roche Ltd: SWOT Analysis
- Figure 63 BGI Genomics Co., Ltd.: Financial Snapshot (2025)
- Figure 64 BGI Genomics Co., Ltd.: SWOT Analysis
- Figure 65 Novogene Co., Ltd.: Financial Snapshot (2025)
- Figure 66 Novogene Co., Ltd.: SWOT Analysis
- Figure 67 Revvity, Inc.: Financial Snapshot (2025)
- Figure 68 Revvity, Inc.: SWOT Analysis
- Figure 69 Macrogen, Inc.: Financial Snapshot (2025)
- Figure 70 Macrogen, Inc.: SWOT Analysis
- Figure 71 QIAGEN N.V.: Financial Snapshot (2025)
- Figure 72 QIAGEN N.V.: SWOT Analysis
- Figure 73 Azenta, Inc.: Financial Snapshot (2025)
- Figure 74 Azenta, Inc.: SWOT Analysis
- Figure 75 GeneDx Holdings Corp.: Financial Snapshot (2025)
- Figure 76 GeneDx Holdings Corp.: SWOT Analysis
- Figure 77 Natera, Inc.: Financial Snapshot (2025)
- Figure 78 Natera, Inc.: SWOT Analysis
- Figure 79 Guardant Health, Inc.: Financial Snapshot (2025)
- Figure 80 Guardant Health, Inc.: SWOT Analysis
- Figure 81 Quest Diagnostics Incorporated: Financial Snapshot (2025)
- Figure 82 Quest Diagnostics Incorporated: SWOT Analysis
